INTRODUCTION
Tuberculosis (TB) is one of the major public health problems globally. An estimated one-third of the world's population is infected with the Mycobacterium tuberculosis, and the disease kills nearly 1.7 million people each year (WHO, 2009 ). On the other hand, HIV is currently, the most important predisposing factor for developing TB in individuals coinfected with M. tuberculosis. Tuberculosis-HIV co-infection is increasing at an alarming rate. In 2006, there were 9.2 million incident tuberculosis cases in the world, and among these 0.7 million cases were HIV-positive. In 2007, there were at least 1.37 million cases of HIV-positive TB i.e. about 15% of the total incidence (WHO, 2009). [1] Tuberculosis is the most common opportunistic infection and the number one cause of death in HIV/AIDS patients in developing countries. Tuberculosis is a major public health problem in India, which accounts for one-fifth of the global TB incident cases. It is estimated that annually around 330,000 Indians die due to TB. [2] The HIV epidemic has led to large increases in the frequency of smear-negative pulmonary tuberculosis, which has poor treatment outcomes and excessive early mortality compared with smear-positive disease. The emergence of resistance to antituberculosis drugs, and particularly of multidrug-resistant TB (MDR-TB), has become a major public health problem in many countries and an obstacle to effective global TB control. There is high prevalence of MDRTB in HIV-seropositive patients with drug toxicities of multiple drugs including antiretroviral drugs treatment (ART) and anti tubercular drugs (AKT). [3, 4] So far, there are very few studies conducted in India. This prospective study was conducted to compare clinical profile and outcome of newly detected pulmonary tuberculosis in HIV-seropositive and HIV-seronegative patients. We conducted a cross-sectional study to address the comparison of pulmonary tuberculosis in HIV and HIV-seronegative patients at tertiary care center in western Maharashtra.
MATERIALS AND METHODS
A cross-sectional study was conducted at tertiary care center in western Maharashtra from May 2010 to April 2012. This was cross-sectional, observational and prospective study conducted at Krishna Institute of Medical Sciences, Karad. The hospital has facilities for tuberculosis and HIV/AIDS diagnosis, treatment and monitoring. The protocol was approved by the Medical Research ethical Committee of Krishna Institute of Medical Sciences University, Karad. Oral informed and written consent was obtained from the patients prior to enrollment.
Study subjects
A total 50 HIV-seronegative patients and 50 HIV-seropositive patients of both genders, with newly diagnosed pulmonary tuberculosis fulfilling inclusion criteria were included in present study. The sample size of 50 was chosen so that at least 50 evaluable subjects would be available in HIV-seropositive patients. The enrollment of HIV negative TB patients was made concurrently till the desired number of HIV-seropositive patients had been admitted.
Aims and objectives
To assess the outcome of pulmonary tuberculosis and to compare with HIV-seropositive and HIV-seronegative patients.
Inclusion criteria
Patients with age > 18 years of both gender, newly detected pulmonary tuberculosis and not previously received AKT were included in present study.
Exclusion criteria
Patients with severely illness, other factors of immunesuppression and those who are already on AKT or defaulter or with relapse were excluded. Major complications of HIV disease like encephalopathy, renal or hepatic disease, malignancy or any end-stage disease and did not have any medical condition that might interfere with the management of the pulmonary tuberculosis like diabetes, convulsions, serious cardiac or renal disease were excluded.
Diagnosis of active pulmonary tuberculosis
Individuals with a history of cough of 3 weeks duration or more and not responding to routine line of management for upper respiratory tract infection were advised to give three sputum samples (usually two spot and one early morning collection) for sputum smear examination for acid-fast bacilli (AFB) using the Ziehl-Neelsen method and the smears were graded as per the World Health Organization (WHO) standards. Smear positive pulmonary tuberculosis patients were diagnosed using the following criteria as per the Revised National Tuberculosis Control Program (RNTCP) guidelines. All patients received DOTS treatment under RNTCP and they were treated with an initial intensive phase lasting for 2 months followed by a continuation phase, which lasted for 4 months. In the intensive phase, three to four anti-TB drugs were administered thrice weekly depending on the category of treatment prescribed; all the thrice, weekly doses were given under direct observation. In the continuation phase, the number of anti-TB drugs administered was reduced to two and only the first dose of the week was given under direct supervision while the remaining two doses in the week were self-administered. All the drugs were administered thrice a week in the following doses (mg): Isoniazid (600), rifampicin (450, 600, if weight more than 60 kg), pyrazinamide (1500), ethambutol (1200).
Detection of HIV infection
The reactivity in the enzyme-linked immunosorbent assay (ELISA) was confirmed by a rapid test (HIVTRI-DOT, Biotech Inc., India). HIV infection was diagnosed using three antigenically different rapid kits as per the national HIV testing policy.
Definition of cases 1. Newly detected pulmonary TB: The diagnosis of tuberculosis was made by a physician, based on presence of symptoms and signs compatible with TB and/or radiological evidence of active TB; demonstration of AFB from a clinical specimen (sputum). Suggestive clinical profile and empirical response to antitubercular therapy (ATT) 2. MDR-TB is defined as resistance to the two most effective first-line TB drugs: Rifampicin and isoniazid. [5] MDR-TB was diagnosed according to the report available from outside 3. Those cases, who had treatment failure were subjected to sputum culture and drug susceptibility tests. (By using the BACTEC MGIT960 instrument optimized for rapid detection of mycobacteria from the sputum. In cases of positive cultures, susceptibility testing for the isolates was done by 5649-AFB susceptibility: SIREP panel by Radiometry) 4. Immune reconstitution syndrome (IRS) was defined as paradoxical clinical deterioration temporally associated with start of antiretroviral therapy, TB -IRIS immune reconstitution inflammatory syndrome (IRIS) was defined as transient worsening or appearance of new symptoms, signs or radiographic manifestations after initiation of highly active antiretroviral therapy (HAART). Tuberculosis is the most frequent pathogen associated with IRIS, of which, lymph node enlargement is the most common manifestation. [6] Laboratory procedure for tuberculosis diagnosis and Hematology Sputum was collected in a plastic leak-proof container and examined for AFB under microscopy using Ziehl-Neelsen (Z.N.) method. The culture and drug susceptibility testing were done for MDR-TB. Table 4 ]. Total 18/50 (36%) patients had a sputum negative at the end of third month and 32/50 (64%) were having sputum positivity or persistent x-ray finding and or clinical deteoriation Table 5 ].
Total 10/50 (20%) and 1/50 (2%) patients were diagnosed with MDR-TB among HIV-seropositive group and HIV-seronegative group, respectively. There was statistical significant difference between two groups with high incidence of MDR-TB among HIV-seropositive group [Chi-square: 9.4697, P = 0.002] [ Table 6 ].
Total 39 patients had abnormal chest radiogram suggestive of active pulmonary tuberculosis in HIV-seropositive group. Total 13 (33.33%) patients had upper lobe involvement in the form of infiltrates, pleural thickening and fibrosis. Total 11 (28.20%) patients had middle and lower lobe involvement in the form of infiltrates and patchy consolidation. Total 3 (7.69%) patients had miliary shadows in both lung fields. Total 5 (12.82%) patients had cavitary lesions in right lung fields. Total 7 (17.94%) patients had bilateral extensive pulmonary tuberculosis (BEPT). Total 22 patients had abnormal chest radiogram suggestive of active pulmonary tuberculosis in HIV-seronegative group. Total 15 (48.38%) patients had upper lobe involvement in the form of infiltrates, pleural thickening and fibrosis. Total 3 (9.67%) patients had middle and lower lobe involvement in the form of infiltrates and patchy consolidation. Total 5 (16.12%) patients had miliary shadows in both lung fields. Total 7 (22.58%) patients had cavitory lesions in right lung fields. Total 1 (3.22%) patients had bilateral extensive pulmonary tuberculosis (BEPT). There was high prevalence of middle and lower lobe lesions and BEPT in patients with HIV-seropositive group patients and upper lobe, miliary shadow and cavitory lesions in HIV-seronegative group patients ['P' <0.02]. The cavitory lesions were significantly low in HIV-seropositive group with low CD+4 counts [ Table 7 ].
Total 25 patients were had hospital stay of <7 days and 25 had >7 days amongst HIV-seropositive group. Total 36 patients were had hospital stay of <7 days and 14 had >7 days amongst HIV-seronegative seropositive group. Duration of stay was significantly more in HIV-seropositive group compared with HIV seronegative-seropositive groups ['P' <0.01].
In multivariate analysis, after controlling age and gender, mortality rate, MDR-TB, duration of hospital stay, middle and lower lobe chest radiographic findings, jaundice and sputum for AFB positivity at the end of three months was significantly higher in HIV-seropositive patients with newly diagnosed pulmonary tuberculosis ('P' < 0.01).
DISCUSSION
The global impact of the converging dual epidemics of tuberculosis (TB) and human immunodeficiency virus (HIV) is one of the major public health challenges. Further, there has been an increase in rates of drug resistant tuberculosis, including multi-drug (MDRTB) and extensively drug resistant TB (XDRTB), which are difficult to treat and contribute to increased mortality. Treatment of HIV-TB co-infection is complex and associated with high pill burden, overlapping drug toxicities, risk of IRIS and challenges related to adherence. In present study, we compared the outcome of pulmonary TB in HIV-seropositive and HIV-seronegative patients. Our results were compared with various Indian and overseas studies. Solomon S et al., reported that 22 (91.67%) of a total of 24 HIV-seropositive pulmonary tuberculosis patients had pulmonary cavities and 21 patients (87.5%) had bacteriological confirmation of tuberculosis. [8] Similarly in the present study there was high prevalence of middle and lower lobe lesions and BEPT in patients with HIV-seropositive group patients and upper lobe, miliary shadow and cavitary lesions in HIV-seronegative group patients ['P' < 0.02]. The cavitory lesions were significantly low in HIV-seropositive group with low CD+4 counts. Patel AK et al., in their study of 50 patients, 40% had only pulmonary TB (PTB) and 25.58% was positive for AFB smear. Sputum smear AFB positivity is low in TB patients having HIV. [9] In contrast, in our study total 26/36 (72.22%) males and 8/14 (57.14%) females had smear positive sputum for AFB in HIV group. Total 16/29 (55.17%) males and 14/21 (66.66%) females patients were positive for sputum for AFB among the HIV-seronegative group, with high prevalence of sputum positivity for AFB. Purohit S D et al. quoted high mortality in HIV/TB infected group (66.6%). [10] Similarly, total 25% male patients and 14.28% females patients died in HIV-seropositive group with relatively low mortality. Mohammad Tahir et al. reported 27% sputum positive for AFB in their study with overall treatment success achieved in 86%. [11] Similarly, 72.22% males and 57.14% females had smear positive sputum for AFB in HIV group. Total 55.17% males and 66.66% female patients were positive for sputum for AFB among HIV-seronegative group with high prevalence of sputum positivity for AFB. Jaryal A et al., in their study of 87 HIV-infected patients with associated tuberculosis stated that early diagnosis of tuberculosis and prompt institution of antitubercular treatment (ATT) reduces mortality and morbidity significantly. [12] These findings are comparable with our study in which there was statistically significant difference with high mortality i n H I V-s e r o p o s i t i v e g r o u p c o m p a r e w i t h HIV-seronegative group [Chi-square: 12.35, P < 0.0001].
Terminal event in HIV-seropositive group was ARDS with respiratory failure. Two patients had developed chronic corpulmonale in HIV-seropositive group patients with BEPT. Perriëns JH et al., concluded that, the efficacy of a short-course regimen of chemotherapy for pulmonary tuberculosis in HIV-seropositive and HIV-seronegative outpatients with their rates of treatment failure were similar. [13] In contrast in present study a total 40 (80%) patients were sputum negative at the end of six month (2 nd follow up) among HIV-seropositive group. Total 49/50 (98%) become a sputum negative at the end of 2 nd follow up 6 month among HIV-seronegative group ['P' = 0.021]. In present study the there was high mortality in HIV-seropositive group compare to HIV-seronegative group ['P' < 0.0001]. Chaisson RE et al. stated that, DOTS is highly efficacious in both HIV-seropositive and seronegative patients. [14] Similarly in present study with success rate of 98% in HIV-seropositive group and 80% in HIV-seronegative seronegative group with total 9/36 (25%) male patients and 2/14 (14.28%) females patients died in HIV-seropositive group with no death amongst in seronegative groups. El-Sadr WM et al., in their study found that, among HIV-infected patients cure and success rate was less and relapse rate was more. [15] Similarly in present study a total 40/50 (80%) patients were sputum negative at the end of six month (2 nd follow up) among HIV-seropositive group. Total 49/50 (98%) become a sputum negative at the end of 2 nd follow up 6 month among seronegative group [16] This review raises serious concerns regarding current recommendations for treatment of HIV-tuberculosis coinfection. In present study a total 40/50 (80%) patients were sputum negative at the end of six month (2 nd follow up) among HIV-seropositive group. Total 49/50 (98%) become a sputum negative at the end of 2 nd follow up 6 month among HIV-seronegative group. Timothy R et al., found that, antiretroviral therapy has a profound effect on lowering the risk of TB in HIV-infected persons, but it can also be associated with immune reconstitution inflammatory disease and unmasking of previously subclinical disease. [17] These findings are comparable with present study, where total 10/50 (20%) patients in HIV-seropositive group and 3/50 (6%) HIV-seronegative group had clinical/Biochemical evidence of jaundices. There was a statistically difference between development of jaundices in HIV and HIV-seronegative group. In present study total 4 male and 4 female patients had IRIS (inflammatory response syndrome) who were on ART and developed new pulmonary infiltrates and findings suggestive of active pulmonary tuberculosis. S. Tripathy et al., in their study found that, at the end of the 6 th month of anti-TB treatment, 62% of the HIV-seropositive and 92% of the HIV negative smear negative patients completed treatment and were asymptomatic. [18] In present study, a total 18/50 (36%) patients had a sputum negative at the end of third month and 32/50 (64%) were having sputum positivity in HIV-seropositive group. Total 47/50 (94%) were sputum negative at the end of third month and 3 were having a sputum positivity in non-HIV group. There was significant difference between two groups for sputum positivity [Chi-square: 36.96, 'P'<0.0001]. Total 9/36 (25%) male patients and 2/14 (14.28%) females patients died in HIV-seropositive group with no death amongst HIV-seronegative groups. There was statistical significant difference for mortality with high mortality in HIV-seropositive group compared with HIV-seronegative group [Chi-square: 12.35, 'P' < 0.0001]. These findings are comparable with our results. Swaminathan S et al. reported that, tuberculosis has a varied clinical presentation in patients with HIV infection as per subjective immunological status. [19] These findings are comparable with our study in which, A total of 33/36 (91.66%) males patients and 12/14 (85.71%) females had CD4 count less than 200 per cubic mm. A total 3/36 (8.33%) males patients and 2/14 (14.28%) females patients had CD4 count more than 200 micml/lt. Mean CD4 count was 128.44 ± 36. Total 39 patients had abnormal chest radiogram suggestive of active pulmonary tuberculosis in HIV-seropositive group. Total of 13 (33.33%) patients had upper lobe involvement in the form of infiltrates, pleural thickening and fibrosis. Total of 11 (28.20%) patients had middle and lower lobe involvement in the form of infiltrates and patchy consolidation. Total of 3 (7.69%) patients had miliary shadows in both lung fields. Total of 5 (12.82%) patients had cavitary lesions in right lung fields. Total of 7 (17.94) patients had BEPT. There was high prevalence of middle-and lower-lobe lesions and BEPT in patients with HIV-seropositive group patients and upper lobe, miliary shadow and cavitary lesions in HIV-seronegative group patients ['P' < 0.02]. The cavitary lesions were significantly low in HIV-seropositive group with low CD+4 counts. Kassim S et al., stated that the HIV-positive patients had lower rates of completion of therapy (65-73%) than seronegative patients (79%), mainly because of increased mortality. [20] Rifampicin-containing short-course chemotherapy for pulmonary tuberculosis is associated with similar cure and recurrence rates in HIV-positive and HIV-negative persons completing 6 months of therapy. However, mortality is significantly increased in all seropositive groups compared with HIV-negative tuberculosis patients. Similarly, in present study a total of 80% patients was sputum negative at the end of 6 th month (2 nd follow up) among HIV-seropositive group and 98% among HIV-seronegative group. Similar to the present study, Bwire R et al., reported that HIV-seropositive status is not a principal factor in delaying sputum conversion among patients receiving intensive phase tuberculosis treatment. [21] Daniel OJ et al., in their study to compare the treatment outcome of TB/HIV-seropositive and TB/HIV-negative patients, Nigeria found that, 58 (16.4%) were HIV seropositive. [22] The cure rate was 76.8% patients. The cure rate was significantly lower in HIV infected compared with HIV seronegative infected TB patients (60.3% vs 80.0%; P = 0.0001). Overall mortality was 5.1%, which was significantly higher in HIV seropositive compared with HIV negative TB patients (15.5% v 3.1%; P = 0.00007). Mortality rate in TB/HIV-seropositive patients was higher than in HIV-negative patients. These findings are similar to our study where cure rate was less in seropositive group with high mortality. Swaminathan S et al., in their study found that at the end of two months of treatment, 91% of seropositive patients had sputum cultures negative for M. tuberculosis. [23] Similarly, in our study, success rate was 80% at the end of the 6 th month. Pili Kamenju et al., in their study of TB-HIV co-infection among of 387 TB patients found that there was significantly higher proportion of deaths among HIV-infected TB patients (29.1% versus 15.2%) than in the HIV-uninfected TB patients (P = 0.005). [24] These findings are comparable with present study. Nagai H et al., reported that, the incidence of HIV seropositivity was 3.2% in all TB patients, 28.6% in miliary TB patients, and 1.0% in typical TB patients. [25] Similarly in present study, a total of 3 (7.69%) patients had miliary shadows in both lung fields in H I V-s e r o p o s i t i v e g r o u p a n d ( 1 6 . 1 2 % ) i n HIV-seronegative group. Hsieh SM et al. reported that, a primary tuberculosis pattern (hilar adenopathy, pleural effusion, middle or lower lobe infiltrates) in the chest radiographs was the most common radiological finding (36.4%) in patients with pulmonary TB. [26] The reactivation pattern (predominant upper-lobe infiltrates with or without cavitation) could only be found in cases of pulmonary TB without extrapulmonary involvement, these findings are comparable with our study. Punnotok J et al., stated that TB were more likely to have strains that are resistant to isoniazid (10.9% vs 3.5%; P < 0.001), rifampicin (9.4% vs 2.9%; P < 0.001), and at least isoniazid and rifampicin (multidrug-resistant TB [MDR-TB]; 5.2% vs 0.4%; P < 0.001). [27] Similarly in our study total 20% and 2% patients were diagnosed to MDR-TB among HIV-seropositive group and HIV-seronegative group, respectively. El-Sony AI et al., reported that the smear-positive cases showed a cure rate of 77.2% and a failure rate of 1%. [28] Cure rates for the smear-positive cases were 68.3% for HIV-positive and 77.6% for HIV-negative patients (P = 0.164). Case f a t a l i t y w a s s i g n i f i c a n t l y h i g h e r a m o n g HIV-positive (12%) than among HIV-negative cases (1.8%) (OR 7.7, 95% CI 3.51-16.8). Similarly success rate of DOTS was 80% in HIV-seropositive patients in present study. Abouya L et al., stated that among HIV-infected patients with CD4 + counts of > or = 400/mm 3 , 200-399/mm 3 , and <200/mm 3 , respectively, the proportions with non-cavitary infiltrates and hilar adenopathy increased significantly, while the proportion with cavitary lesions decreased significantly. [29] Similarly, in present study there was high prevalence of middle-and lower-lobe lesions and BEPT in patients with HIV-seropositive group patients and upper lobe, miliary shadow and cavitory lesions in HIV-seronegative group patients ['P' < 0.02]. The cavitory lesions were significantly low in HIV-seropositive group with low CD+4 counts. Ahmadi F et al., reported that, atypical radiological features are explained by immunoradiological correlation, where the miliary disease, pleural effusion and lympahdenopathy occurs mostly in patients with CD4 lymphocyte level below 200/mm≥, while the cavitations occur more frequently with CD4 lymphocyte level above 200/mm≥. [30] Rajasekaran S et al., reported that, prevalence of HIV coinfection with MDR-TB was found to be high among chronic TB patients. [31] In present study we have total 20% patients, who were diagnosed with MDR-TB among HIV-seropositive group. Similarly, Deivanayagam CN., et al. reported 33.9% MDR-TB patients.
[32] EU Nwonwu et al., reported, most common radiological features was cavitary lesions (64.1%), patchy opacities (44.4%), and hilar opacities (38.5%) with PTB/HIV co-infection. [33] Similarly in our study total of 7 (17.94) patients had BEPT in PTB/HIV co-infection. R Prasad et al., in their study observed that 90.1% patients remained asymptomatic, 7.2% patients had relapsed and 2.6% patients died during follow-up, and these findings are comparable with our results. [34] Datta BS et al., reported 52 (5.7%) cases of MDR-TB, among which eight (15.3%) were diagnosed as XDR-TB on the basis of drug susceptibility testing. [35] In present study, we have a total of 20% and 2% patients diagnosed to MDR-TB among HIV-seropositive group and HIV-seronegative group, respectively. To improve the performance and impact of TB-control program, in the face of HIV co-infection and other constraints on DOTS, the World Health Organization has launched the revised 'Stop TB Strategy'. The new strategy, to be implemented via the Global Plan to Stop TB (2006 -2015 , includes intensified TB-case finding, treatment of latent TB infection with isoniazid, prevention of HIV infection, cotrimoxazole preventive therapy and ART.
CONCLUSIONS
HIV infection is the strongest of all known risk factors for the development of tuberculosis. We found high prevalence of MDR pulmonary tuberculosis in HIV-seropositive patients in this setting. Atypical chest radiograph suggestive of tuberculosis was common findings in HIV/tuberculosis co-infected patients.
Mortality was significantly high in HIV-seropositive patients than HIV-seronegative patients. Jaundice was more prevalent in HIV-seropositive patients than HIV-seronegative patients with newly detected pulmonary TB on anti-tubercular treatment, which was contributed by ART in HIV-seropositive group. There was high prevalence of middle-and lower-lobe lesions and BEPT in patients with HIV-seropositive group patients and upper lobe, miliary shadow and cavitory lesions in HIV-seronegative group patients. Tubercular co-infection is common in HIV infected and more so with falling CD4 cell level. The cavitory lesions were significantly low in HIV-seropositive group with low CD+4 counts. Duration of stay was significantly more in HIV-seropositive group compared with HIV-seronegative and seropositive groups. Success rate of DOTS was less in HIV-seropositive group at the end of the 6 th month. All patients seeking HIV care merit meticulous screening for tuberculosis and timely institution of appropriate treatment regimens for the dual diseases. We strongly support for strengthening of linkages between the RNTCP and National AIDS Control Program that would contribute towards early case detection and early treatment of the two diseases, thereby significantly reducing the morbidity and mortality associated with HIV/tuberculosis co-infected. The adequate knowledge of the manifestations of tuberculosis in HIV-infected patients is necessary for optimal management and to reduce mortality and morbidity.
